You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

791 Results
Document
Jul 2019
Document
Jul 2019
Document
Jul 2019
Document
Jul 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    lorlatinib - For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lorlatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Guidelines and Advice
Status: Current
Version: N/A
Aug 2019
Document
Aug 2019
Guidelines and Advice
Status: Current
ID: 21-4
Version: N/A
Aug 2019
Document
Sep 2019
Document
Sep 2019

Pages